pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Omlyclo · news · pharmadog
← back to Omlyclo
News mentioning Omlyclo
11
stories
28d
Protein degrader specialist Lycia prices $318M IPO
biopharma dive
28d
Roche affirms sales outlook amid doubts about its future
biopharma dive
28d
Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T asset
biospace
Oct 20, 26
Lycia aims for $228M IPO to generate data on food allergy rival to Xolair
fiercebiotech
Sep 22, 26
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
biopharma dive
Sep 22, 26
Celldex monoclonal antibody rebounds with pair of phase 3 wins for chronic skin condition
fiercebiotech
Sep 21, 26
Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial
endpoints
Sep 21, 26
Cue chalks up phase 2 hives win for Xolair challenger
fiercebiotech
Jul 28, 26
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
fiercebiotech
Jul 23, 26
Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
biospace
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive